Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Presence in pharmaceutical industry hotbed allows Elevar to recruit top talent as it continues toward a commercial launch of cancer...
SAN FRANCISCO and DALY CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization...
SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that...
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer...
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical...
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Philips Intracardiac Echocardiography Catheter – VeriSight Pro Intravascular ultrasound (IVUS) catheter CIED infection March 6, 2023 Preliminary results of large-scale...
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity...
Live conference call on Friday, March 10 at 8:30 a.m. ETMIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:...
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics...
Figure 1 Fluoresceine angiogram data from three animals treated with NM3086 (bottom) and three that received placebo control. The picture...
Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to...
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless...
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement...
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
JERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Management to provide an update on its regulatory and partnering strategy for the United States and EuropeCHARLOTTESVILLE, Va., March 02,...
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs...
Engagement with Interventional Radiologists Reaches Highest Level Yet as Company Continues to Progress Through Regulatory and Clinical Phases; Company Seeking...